Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Celgene will pay $35 million to fund R&D on VentiRx Pharmaceuticals’ VTX-2337, a small-molecule Toll-like receptor 8 agonist being developed as a cancer immunotherapy. During an option period, Celgene will have an exclusive right to acquire the Seattle-based firm. Separately, Celgene will work with the Leukemia & Lymphoma Society to identify and fund promising blood cancer research projects. The pact is the first in a new LLS program of venture philanthropy projects with the drug industry.
This article has been sent to the following recipient: